COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,612 Articles (22,913 medRxiv, 8,699 bioRxiv)

Most recent first Previous |  Page 2054: Articles 20531-20540  | Next

Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first six months of the COVID-19 pandemic
Lubin, J. H., Zardecki, C., Dolan, E. M., Lu, C., Shen, Z., Dutta, S., Westbrook, J. D., Hudson, B. P., Goodsell, D. S., Williams, J. K., Voigt, M., Sarma, V., Xie, L., Venkatachalam, T., Arnold, S., Alfaro Alvarado, L. H., Catalfano, K., Khan, A., McCarthy, E., Staggers, S., Tinsley, B., Trudeau, A., Singh, J., Whitmore, L., Zheng, H., Benedek, M., Currier, J., Dresel, M., Duvvuru, A., Dyszel, B., Fingar, E., Hennen, E. M., Kirsch, M., Khan, A. A., Labrie-Cleary, C., Laporte, S., Lenkeit, E., Martin, K., Orellana, M., Ortiz-Alvarez de la Campa, M., Paredes, I., Wheeler, B., Rupert, A., Sam, A., See, K., Soto Zapata, S., Craig, P. A., Hall, B. L., Jiang, J., Koeppe, J. R., Mills, S. A., Pikaart, M. J., Roberts, R., Bromberg, Y., Hoyer, J. S., Duffy, S., Tischfield, J., Ruiz, F. X., Arnold, E., Baum, J., Sandberg, J., Brannigan, G., Khare, S. D., Burley, S. K.
10.1101/2020.12.01.406637 — Posted: 2020-12-01
Designed proteins assemble antibodies into modular nanocages
Divine, R., Dang, H. V., Ueda, G., Fallas, J. A., Vulovic, I., Sheffler, W., Saini, S., Zhao, Y. T., Raj, I. X., Morawski, P. A., Jennewein, M. F., Homad, L. J., Wan, Y.-H., Tooley, M. R., Seeger, F., Fahning, M. L., Etemadi, A., Lazarovits, J., Roederer, A., Walls, A. C., Stewart, L., Mazloomi, M., King, N. P., Campbell, D. J., McGuire, A. T., Stamatatos, L., Ruohola-Baker, H., Mathieu, J., Veesler, D., Baker, D.
10.1101/2020.12.01.406611 — Posted: 2020-12-01
Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.
Ho, J. S. Y., Mok, B. W.-Y., Campisi, L., Jordan, T., Yildiz, S., Parameswaran, S., Wayman, J. A., Gaudreault, N. N., Meekins, D. A., Indran, S. V., Morozov, I., Trujillo, J. D., Fstkchyan, Y. S., Rathnasinghe, R., Zhu, Z., Zheng, S., Zhao, N., White, K., Ray-Jones, H., Malysheva, V., Thiecke, M. J., Lau, S.-Y., Liu, H., Zhang, A. J., Lee, A. C.-Y., Liu, W.-C., Aydillo, T., Melo, B. S., Guccione, E., Sebra, R., Shum, E., Bakker, J., Kaufman, D. A., Moreira, A., Carossino, M., Balasuriya, U. B. R., Byun, M., Miraldi, E. R., Albrecht, R. A., Schotsaert, M., Garcia-Sastre, A., Chanda, S. K., Jeyasekharan, A. D., TenOever, B. R., Spivakov, M., Weirauch, M. T., Heinz, S., Chen, H., Benner, C., Richt, J. A., Marazzi, I.
10.1101/2020.12.01.404483 — Posted: 2020-12-01
A pomegranate peel extract as inhibitor of SARS-CoV-2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs
Tito, A., Colantuono, A., Pirone, L., Pedone, E. M., Intartaglia, D., Giamundo, G., Conte, I., Vitaglione, P., Apone, F.
10.1101/2020.12.01.406116 — Posted: 2020-12-01
Differential effects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro
Xu, C., Wang, A., Hoskin, E. R., Cugini, C., Markowitz, K., Chang, T. L., Fine, D. H.
10.1101/2020.12.01.405662 — Posted: 2020-12-01 Discussion: Offsite
Neutrophil and monocyte dysfunctional effector response towards bacterial challenge in critically-ill COVID-19 patients
Mairpady Shambat, S., Gomez-Mejia, A., Schweizer, T. A., Huemer, M., Chang, C.-C., Acevedo, C., Bergada Pijuan, J., Vulin, C., Miroshnikova, N., Hofmanner, D. A., Wendel Garcia, P. D., Hilty, M. P., Buehler, P. K., Schuepbach, R. A., Brugger, S. D., Zinkernagel, A. S.
10.1101/2020.12.01.406306 — Posted: 2020-12-01 Discussion: Onsite | Offsite
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. H., Choudhary, M. C., Dingens, A. S., Li, J. Z., Bloom, J. D.
10.1101/2020.11.30.405472 — Posted: 2020-12-01
Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2
Mugnai, M. L., Templeton, C., Elber, R., Thirumalai, D.
10.1101/2020.11.30.405340 — Posted: 2020-12-01
Guidelines for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples
Kubik, S., Marques, A. C., Xing, X., Silvery, J., Bertelli, C., De Maio, F., Pournaras, S., Burr, T., Duffourd, Y., Siemens, H., Alloui, C., Song, L., Wenger, Y., Saitta, A., Macheret, M., Smith, E. W., Menu, P., Brayer, M., Steinmetz, L. M., Si-Mohammed, A., Chuisseu, J., Stevens, R., Constantoulakis, P., Sali, M., Greub, G., Tiemann, C., Pelechano, V., Willig, A., Xu, Z.
10.1101/2020.12.01.405738 — Posted: 2020-12-01
The N-glycosylation sites and Glycan-binding ability of S-protein in SARS-CoV-2 Coronavirus
Chen, W., Hui, Z., Ren, X., Luo, Y., Shu, J., Yu, H., Li, Z.
10.1101/2020.12.01.406025 — Posted: 2020-12-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).